





The Dow Jones Industrial Average (DJINDICES: ^DJI) may be the most elite club in the stock market. The vaunted index holds only 30 blue chip stocks, making it a great source if youre looking for reliable industry leaders that pay dividends. In fact, one time-tested investment strategy known as the Dogs of the Dow calls for buying stock in the 10 highest dividend-yielding Dow Jones stocks and rebalancing annually.Where to invest $1,000 right now? Our analyst team just revealed what they believe ...
Johnson & Johnson (NYSE: JNJ) is an elite dividend stock. The healthcare giant has increased its dividend payment for 62 years in a row. That qualifies it as a Dividend King, a company that has increased its dividend payment annually for at least 50 years. The company also has a higher-yielding payout. At around 3.4%, its almost triple the S&P 500s (SNPINDEX: ^GSPC) dividend yield, which is near a more than 20-year low at 1.2%. Where to invest $1,000 right now? Our analyst team just revealed ...
Checking a companys vital signs before investing in its stock for dividend income is essential. If the underlying company isnt financially healthy, its dividend probably wont last very long. That wont be a problem with Johnson & Johnson (NYSE: JNJ) and Medtronic (NYSE: MDT). Theyre healthy companies that should continue to pay durable dividends in the decades ahead, making them great income investments. As healthy as it gets Johnson & Johnson is among the worlds healthiest companies. The ...
J&J (JNJ) is set to buy Shockwave Medical (SWAV). FDA approves AstraZenecas (AZN) Enhertu for metastatic HER2-positive solid tumors.
Johnson & Johnson (NYSE:JNJ) will report first quarter results next Tuesday, 16 April, hot on the heels of its acquisition of Shockwave Medical. This...
Shockwave Medical (SWAV) announces the real-world results of the REDUCER-I study, which is intended to collect long-term outcomes on Shockwave Reducer, a novel treatment for refractory angina.
J&Js (JNJ) proposed acquisition of Shockwave Medical (SWAV) is expected to strengthen its Medtech cardiovascular portfolio.
Johnson & Johnson (NYSE:JNJ) (J&J) will bolster its portfolio of medical devices targeting heart disease with its $13.1 billion acquisition of Shockwave...
Je 335 Dollar (308,72 Euro) solle pro Aktie gezahlt werden, teilte Johnson & Johnson am Freitag in New Brunswick (Bundesstaat New Jersey) mit. Das wäre etwas mehr als der Schlusskurs von knapp 320 Dollar vom ...
Shockwave Medical entwickelt Geräte gegen Herz-Kreislauf-Krankheiten und passt in das Profil von Johnson & Johnson. Für den US-Konzern ist es die größte Übernahme seit zwei Jahren.
Johnson & Johnson on Friday agreed to buy Shockwave Medical for $12.5 billion to broaden its portfolio of medical devices used in treating heart diseases.
Johnson & Johnson agrees to acquire Shockwave Medical for $13.1 billion
Johnson & Johnson to buy Shockwave Medical in $12.5 billion deal
News of healthcare behemoth Johnson & Johnson (JNJ) acquiring medical device company ShockWave Medical (SWAV) for $13.1 billion made headlines this morning.
ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.
Shockwave Medical shares are trading more than 3% higher in Wednesday’s session, having soared more than 10% since it was announced Johnson & Johnson...
Die wichtigsten amerikanischen Indizes befinden sich weiter in Schlagdistanz zu den bisherigen Bestmarken. Dow Jones und Nasdaq 100 mussten dennoch am Dienstag nachgeben. Vor allem Einzeltitel aus ...
Die wichtigsten amerikanischen Indizes befinden sich weiter in Schlagdistanz zu den bisherigen Bestmarken. Dow Jones und Nasdaq 100 mussten dennoch am Dienstag nachgeben. Vor allem Einzeltitel aus dem Pharma-, Biotech- und Medizintechnik-Bereich konn...
Die wichtigsten amerikanischen Indizes befinden sich weiter in Schlagdistanz zu den bisherigen Bestmarken. Dow Jones und Nasdaq 100 mussten dennoch am Dienstag nachgeben. Vor allem Einzeltitel aus dem Pharma-, Biotech- und Medizintechnik-Bereich konnten teilweise mit deutlichen Kursgewinnen aufwarten – auch aufgrund von frischen Übernahmegerüchten.
Kulmbach (www.aktiencheck.de) - Shockwave Medical-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie von Shockwave Medical Inc. (ISIN: US82489T1043, WKN: A2PEF3, Ticker-Symbol: 36M, NASDAQ-Symbol: SWAV) unter die Lupe. [mehr]
Johnson & Johnson considers deal for Shockwave Medical (SWAV) – WSJ
Johnson & Johnson considers deal to buy Shockwave Medical, WSJ reports
Shockwave Medical stock target raised to $310 on market opportunity
GigaCloud stock, ELF Beauty, Caterpillar, Shockwave Medical and Ryanair are among the 13 new stocks on IBD watchlists Friday.
ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.